← Back to all media

Beware the pitfalls for non-specialist investors in the #biotechnology space warns International Biotech Trust

There are many ways a biotech company can succeed, but there are many more ways it can fail. Since most early-stage drug development projects will unfortunately fail, investors need to be able to spot the substandard ones and, crucially, avoid the mediocre ones that can linger on to become costly lessons.